2019 EAN Abstract – Phase 1b/2 Study of RG6206 A Phase 1b/2 study of the anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy: A 72-week treatment update View the Full PDF